secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K/A
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001437749-24-026664
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01, 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Q2 cash $218.7M; R&D $7.9M; IPO net $107.9M; Phase 2 enrollment on track
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at YE 2023.
- R&D expenses $7.9M in Q2, down from $9.5M YoY, driven by lower consulting/manufacturing offset by Phase 2 costs.
- G&A expenses $3.0M, up from $1.6M YoY on higher consulting and personnel costs.
- IPO completed in April 2024 with net proceeds of $107.9M.
- Enrollment ongoing in Phase 2 VISTA trial of PIPE-307 for RRMS; expects completion in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924026664/0001437749-24-026664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924026664/cont20240813_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer